| SKIP001179 | |
| SKIP ID | SKIP001179 |
| Organism(En) | - |
| Organism(Ja) | - |
| Cell Type(En) | - |
| Cell Type(Ja) | - |
| Cell Tissue(En) | - |
| Cell Tissue(Ja) | - |
| Cell Origin | Diseased |
| Cell Name 1(En) | 64FSDNC1 |
| Cell Name 1(Ja) | 64FSDNC1 |
| Cell Name 2(En) | DOX3 hiPSCs |
| Cell Name 2(Ja) | DOX3 hiPSCs |
| Disease Name 1(Ja) | 乳癌 |
| ICD Code 1 | C509 |
| Disease Name 1(En) | breast cancer |
| OMIM1 | 114480 |
| Disease Name 2(Ja) | - |
| ICD Code 2 | - |
| Disease Name 2(En) | - |
| OMIM 2 | - |
| Disease Name 3(Ja) | - |
| ICD Code 3 | - |
| Disease Name 3(En) | - |
| OMIM 3 | - |
| Age | 52 |
| Age Range | 50-59 |
| Sex | Female |
| Race(En) | - |
| Race(Ja) | - |
| Genetic Diagnosis | No |
| Not Detected | No |
| Description(En) | hiPSC-CMs derived from a patient who received doxorubicin but did not experience cardiotoxicity. |
| Description(Ja) | ドキソルビシン治療による心毒性が見られない乳癌患者由来iPS細胞 |
| Cell Morphology | human ES-like |
| Grade | Research Grade |
| Vector | Sendai virus |
| Transgene | Oct3/4, Klf4, Sox2, c-Myc |
| Adhesiveness | - |
| Feeder | No |
| Feeder Cell | - |
| Medium | E8 medium |
| Genome Editing | - |
| CO2 | 5% |
| Mycoplasma | Negative |
| Detection of Contaminants Mycoplasma | - |
| Pluripotent Markers | Yes |
| Pluripotent Markers Assay | immunostaining, RT-PCR, Flow cytometry |
| in vitro Differentiation | Yes |
| in vitro Differentiation Assay | - |
| in vivo Differentiation | Yes |
| in vivo Differentiation Assay | teratoma |
| Other 1 Assay | - |
| Other 1 Assay Method | - |
| Other 2 Assay | - |
| Other 2 Assay Method | - |
| Other 3 Assay | - |
| Other 3 Assay Method | - |
| Karyotype | - |
| Karyotype Assay | - |
| Remaining Vector Detection | - |
| Remaining Vector Detection Assay | - |
| STR | - |
| HLA | - |
| Stem Cell Transcriptome analysis | - |
| Stem Cell Transcriptome analysis Assay | - |
| Author Name(En) | Joseph C Wu |
| Author Name(Ja) | Joseph C Wu |
| Author Organization(En) | Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA. |
| Author Organization(Ja) | Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA. |
| Author Contact Email | - |
| PI Organization(En) | Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA. |
| PI Organization(Ja) | Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA. |
| PI Name(En) | Paul W Burridge |
| PI Name(Ja) | Paul W Burridge |
| PI Contact Email | - |
| Availability | Information Only |
| Provider Organization(En) | Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA. |
| Provider Organization(Ja) | Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA. |
| Provider Email | joewu[at]stanford[dot]edu |
| Provider URL | - |
| Ethical Statement(En) | - |
| Ethical Statement(Ja) | - |
| Terms of Use(En) | - |
| Terms of Use(Ja) | - |
| PubMed ID | 27089514 |
| DOI | 10.1038/nm.4087 |
| Title | Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. |
| Authors | Burridge PW, Li YF, Matsa E, Wu H, Ong SG, Sharma A, Holmstrom A, Chang AC, Coronado MJ, Ebert AD, Knowles JW, Telli ML, Witteles RM, Blau HM, Bernstein D, Altman RB, Wu JC |
| Journal | Nat Med |
| Year | 2016 |
| Volume | 22 |
| Issue | 5 |
| Pages | 547-56 |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/27089514 |
| Free input | - |
| Note | - |